Chastain Daniel B, Henderson Harold, Stover Kayla R
Phoebe Putney Memorial Hospital, Department of Pharmacy, Albany, GA, USA.
University of Mississippi Medical Center, Department of Medicine-Infectious Diseases, Jackson, MS, USA.
Open AIDS J. 2015 Mar 31;9:23-37. doi: 10.2174/1874613601509010023. eCollection 2015.
Risk and manifestations of cardiovascular disease (CVD) in patients infected with human immunodeficiency virus (HIV) will continue to evolve as improved treatments and life expectancy of these patients increases. Although initiation of antiretroviral (ARV) therapy has been shown to reduce this risk, some ARV medications may induce metabolic abnormalities, further compounding the risk of CVD. In this patient population, both pharmacologic and nonpharmacologic strategies should be employed to treat and reduce further risk of CVD. This review summarizes epidemiology data of the risk factors and development of CVD in HIV and provides recommendations to manage CVD in HIV-infected patients.
随着针对感染人类免疫缺陷病毒（HIV）患者的治疗方法不断改进以及患者预期寿命的延长，HIV感染患者心血管疾病（CVD）的风险和表现将持续演变。尽管抗逆转录病毒（ARV）疗法已被证明可降低这种风险，但一些ARV药物可能会诱发代谢异常，从而进一步增加CVD风险。对于这一患者群体，应采用药物和非药物策略来治疗并进一步降低CVD风险。本综述总结了HIV患者CVD风险因素和发病情况的流行病学数据，并为管理HIV感染患者的CVD提供了建议。
